Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech hopes to see potential improved delivery of Lucentis in eye implant

This article was originally published in Clinica

Executive Summary

Pharma company Genentech is developing an intraocular implant for the delivery of its age-related macular degeneration (AMD) drug Lucentis (ranibizumab) over a longer period, thereby reducing the dosing frequency. Although Genentech has not discussed the strategy behind the move, it is possible that migrating patients onto the device-delivered form of Lucentis could not only be a useful part of life-cycle management for the drug, but might also encourage patients to seek Lucentis, rather than the similar but much cheaper vascular endothelial growth factor inhibitor, Avastin, another Genentech product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098416

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel